Alyftrek 10-50-125 MG tablet 14S
Ended Awarded Last action
- Contract number
- SPE2DR26FDDS5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $42,850
Award facts
- Contract value 100% obligated
- $42,850.06 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $42.85K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for ALYFTREK 10-50-125 mg tablets (14-count packaging). The delivery order was issued on January 9, 2026, with an ultimate completion date of January 12, 2026, under firm fixed-price terms with no set-aside designation. This award leverages DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion DLA acquisition strategy designed to establish multiple regional prime vendor contractors supplying comprehensive pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial performance as a critical supplier within the federal pharmaceutical supply chain, with its PPV-G GEN V IDC ceiling valued at $499.999 billion through December 31, 2036. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables supporting military healthcare operations globally. As an established performer on numerous prior delivery orders issued by DLA's Medical Supply Chain division, DMS Pharmaceutical Group operates without identified subcontractors, positioning it to fulfill the diverse and specialized pharmaceutical requirements necessary for Department of Defense medical operations.
Quick answers
Who was awarded contract SPE2DR26FDDS5?
SPE2DR26FDDS5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 9, 2026.
How much is contract SPE2DR26FDDS5 worth?
The government has obligated $42,850 on SPE2DR26FDDS5.
Is contract SPE2DR26FDDS5 an order under another contract?
Yes. SPE2DR26FDDS5 is a delivery order under SPE2DR25D9102, an indefinite delivery contract.
Was contract SPE2DR26FDDS5 competed?
The extent of competition for SPE2DR26FDDS5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award